Heidi Overton Affirms MMR Safety and Inherits Three FDA Files

Dr. Heidi Overton told senators on September 24 that the MMR vaccine is safe and effective, then declined to say President Trump was wrong to call it lethal. The White House domestic policy aide, nominated to run the Food and Drug Administration, spent about two hours before the Senate health committee walking around the three files she would inherit if confirmed.

Those files are not theoretical. Measles is at a post-elimination high, the agency is running a new safety study of mifepristone, and investigators are still tracing how iceberg lettuce sickened thousands this summer. Overton affirmed licensed products, refused to prejudge the open review, and would not say an IUD is birth control rather than abortion.

3,659 Measles Cases and a Licensed MMR Shot

As of September 24, CDC measles case counts for 2026 stood at 3,659 confirmed infections, already 1,370 more than the 2,289 recorded in all of 2025. Forty outbreaks this year account for 95% of the cases (3,478 of 3,659). Ninety-five percent of patients were unvaccinated or had unknown shots. Nine percent (327 of 3,659) were hospitalized. CDC lists one measles death in 2026, a figure it says may change, after three deaths in 2025.

MEASLES COUNTS CDC HAS POSTED

Children and teens ages 5 to 19 make up 43% of this year’s cases (1,577). Adults 20 and older are 38% (1,407). Children under 5 are 18% (656). CDC declared measles eliminated in the United States in 2000. This year’s tally has already cleared every full year in that era that the agency has posted beside it.

Sen. Bill Cassidy, a Louisiana physician who chairs the committee, opened on the August 10 order Overton stood behind in the Oval Office. Trump called for limiting routine childhood shots to 11 diseases and splitting the combined measles, mumps, and rubella vaccine into three shots once separate products exist here. They do not exist in the United States now. Cassidy had called her role in that ceremony almost disqualifying, and he has said the order is wrong.

The MMR vaccine is not lethal. It is safe and effective. The MMR vaccine is currently licensed and approved by the FDA. It is safe and effective, and it is our best tool right now in the public health response to the measles outbreak. It is 97% effective in stopping transmission of the virus after two doses.

Heidi Overton, FDA commissioner nominee, Senate HELP hearing, September 24, 2026

Asked whether any vaccine on the U.S. market is unsafe, she said every one is safe and effective according to the FDA. Asked what she would do if the president wanted her to break that, she said she would give him her best advice and follow the statutory tests for safety and efficacy on each product. She did not say he was wrong. That is the bind confirmation would write into the job: the licensed combination shot is the tool against 3,659 cases, and the order she helped stage still asks manufacturers for products that are not on the shelf.

She Wrote That Mail-Order Mifepristone Was Dangerous

On mifepristone, Overton would not give the same plain sentence. Sen. Patty Murray of Washington asked whether she agreed the drug is safe and effective. Overton said it was approved as having met the agency’s standards. Pressed to say whether she agreed, she said a commissioner would abide by those statutory standards. Murray then held up Overton’s own 2023 brief on chemical abortion, written at the America First Policy Institute with Matias Perttula and posted February 27, 2023.

Although chemical abortions pose serious risks to women, with 1 in 5 experiencing adverse effects, the Food and Drug Administration (FDA) has expanded access to chemical abortions over the past two years.

Heidi Overton, America First Policy Institute issue brief, February 27, 2023

The brief called mail delivery dangerous to women and described retail-pharmacy dispensing as abortion-on-demand that removes safeguards. It cited then-current CDC figures that medication abortion made up 64% of abortions before 10 weeks and 52% of all abortions in 2020. Overton has also called the 2022 Dobbs decision a huge victory for life. John Mize, chief executive of Americans United for Life, said after the nomination that he had spoken with her five or six times and was optimistic she would be a pro-life FDA commissioner.

In the hearing she said she has always been driven by data, and that the 2023 paper followed a change in how the drug was accessed. She would not prejudge whether the label or the Risk Evaluation and Mitigation Strategy should move, because a safety study is open. That study is the file. Health Secretary Robert F. Kennedy Jr. and then-commissioner Marty Makary told Republican state attorneys general in September 2025 that the agency would examine the current REMS. FDA questions and answers on mifepristone, updated around the hearing, still say the drug is safe when used as directed, that periodic postmarketing reviews have not found new safety concerns through 70 days of pregnancy, and that the safety study is underway.

As of April 2026, the agency said it was still gathering data with enough power for a controlled analysis, then would explore the files, check integrity, run the numbers, and decide whether the REMS needs a substantive change. The same page records 36 reports of deaths in patients associated with mifepristone from the September 2000 approval through December 31, 2024, including two ectopic pregnancies and several fatal infections. FDA says those events cannot with certainty be blamed on the drug, because other medicines, other procedures, other illnesses, and missing clinical detail sit in the same files, and it did not identify a new safety signal.

Researchers at the Johns Hopkins Bloomberg School of Public Health, writing in January after reading 5,239 pages of internal FDA files (264 documents from June 2011 to January 2023), found the REMS had been shaped by staff scientists and a cautious reading of evidence, including the January 3, 2023, shift that dropped in-person dispensing and added pharmacy certification. Overton would inherit both that paper trail and a review her 2023 brief already answered in political language.

WHAT THE CURRENT MIFEPRISTONE REMS STILL REQUIRES

• Certified prescribers: Only a provider who meets FDA qualifications and signs a prescriber agreement may write the drug.
• Patient agreement: The patient and provider must review and sign a form that explains the regimen’s risks before the prescription is issued.
• Closed dispensing: The tablets may leave only under a certified prescriber or from a certified pharmacy filling that prescriber’s order.
• Tracked shipment: Certified pharmacies must ship with tracking and get the drug to the patient in a timely way.

Republicans on the committee, including Cassidy, have also circulated a report arguing that some manufacturers may not be meeting those rules. Overton told Sen. Jim Banks of Indiana that, if confirmed, she would make sure every company follows the law. That pledge is how a safety study becomes a tighter REMS without a public finding that the tablet itself failed its 2000 approval.

FDA Is Still Tracing How Iceberg Lettuce Got Contaminated

Murray then turned to food. The CDC final cyclospora outbreak update on September 11 closed the case count on the summer’s iceberg lettuce cluster at 12,883 laboratory-confirmed illnesses in 21 states, with at least 570 hospitalizations and two deaths in Michigan. Onsets ran from June 14 to August 17. Epidemiologic and traceback work pointed to iceberg lettuce from Taylor Farms de Mexico, including shredded product served at Taco Bell and bagged Marketside salads. Taylor Farms recalled central-Mexico iceberg lettuce on July 17. CDC said more than 1,000 infections occurred in a single day at the peak before that recall. FDA is still investigating how the lettuce was contaminated.

THE SUMMER LETTUCE CLUSTER, FINAL CDC COUNT

• Illnesses: 12,883 laboratory-confirmed cases across 21 states.
• Hospital care: At least 570 people admitted.
• Deaths: Two, both reported in Michigan.
• Product: Iceberg lettuce processed by Taylor Farms de Mexico, recalled July 17.

Murray said the summer also brought an egg recall, E. coli in frozen blueberries, and infant-formula recalls, and she tied the pile-up to staffing. She said the White House and DOGE pushed out more than 4,600 FDA workers, that the agency is trying to hire back at least 3,500, and that the cut is nearly 17% in a year and a half. She put the Human Foods Program at about 1,700 people, 13% below the start of 2025. Overton, who has not worked inside the agency, said she did not know that shop’s headcount and put the whole FDA at about 16,000. Asked which office hunts these outbreaks, she guessed a food safety and inspection center. Murray named the Coordinated Outbreak Response and Evaluation Network, CORE, and said it has to be fully staffed.

Coming off a summer filled with massive foodborne illness outbreaks, I asked Trump’s nominee to lead the FDA basic questions about its human foods program. She didn’t know the answers.

Coming off a summer filled with massive foodborne illness outbreaks, I asked Trump's nominee to lead the FDA basic questions about its human foods program. She didn't know the answers.

Heidi Overton is unqualified for this role. I'm voting NO. pic.twitter.com/Pb2xmWHH7z

— Senator Patty Murray (@PattyMurray) September 25, 2026

A commissioner who cannot name CORE on day one still owns import inspections, produce traceback, and the foreign-facility user fees Overton said the budget already requests. The outbreak alert is closed. The contamination file is not, and it is larger than any cyclospora cluster CDC has closed in the United States.

From Gallup High School to the Oval Office

Overton is a Gallup High School graduate, class of 2007, who went through the University of New Mexico’s combined B.A./M.D. track, finishing her medical degree in 2015. Gov. Susana Martinez appointed her a student regent. She trained as a general surgery resident at Johns Hopkins, logged 300 surgical cases, and took a Ph.D. in clinical investigation at the Bloomberg School of Public Health. She is board-certified in public health and general preventive medicine. She was a White House fellow in 2019 and 2020, then spent the Biden years as chief policy officer and vice chair of AFPI’s Center for a Healthy America. She returned in 2025 as deputy assistant to the president for domestic policy and helped run the Make America Healthy Again commission’s report and strategy.

THE PATH TO THE WITNESS TABLE

1. 2019 to 2020: Serves as a White House fellow in the Office of American Innovation and the Domestic Policy Council.
2. February 27, 2023: Publishes the AFPI brief calling expanded medication-abortion access a danger to women.
3. January 2025: Returns as deputy assistant to the president for domestic policy.
4. May 2026: Marty Makary resigns as FDA commissioner after about 13 months; Kyle Diamantas becomes acting commissioner.
5. August 10, 2026: Stands in the Oval Office as Trump signs the childhood-vaccine order that calls for splitting MMR.
6. August 19, 2026: Trump nominates her to lead FDA, calling her a rockstar in a Truth Social post.
7. September 24, 2026: Testifies for about two hours before the Senate health committee.

She is a physician-policy aide, not a career center director. Senators also pressed her on flavored e-cigarette authorizations, another unfinished Makary-era fight. The through line is the same: she would take a political White House portfolio into an agency that still has to license shots, police a REMS, and inspect lettuce.

Can the Nominee Tell the President He Is Wrong?

Sen. Maggie Hassan of New Hampshire asked three times, in different words, whether the president can be wrong. Overton said the president sets policy direction, works with advisers, and wants the best decision for Americans. Hassan cut her off. Cassidy asked the same loyalty question through the MMR example and got the licensed-product answer, not a correction of the Oval Office line. Sen. Ed Markey of Massachusetts asked why she had not corrected the president at the signing; she said he was providing additional options.

Mail-order mifepristone, an IUD as contraception, and a combined MMR shot are clinical questions a confirmation hearing can answer in a sentence. Overton answered the third with the label. She routed the first through an open study. She twice declined to say an IUD is birth control rather than an abortifacient, telling Murray she would be briefed on prior agency decisions if confirmed. Murray called that outrageous. Those non-answers are not a sideshow. They are how a commissioner would talk on the first day a White House claim collides with a review staff file.

Her vaccine answers also cut against the coalition that wanted FDA to treat licensed shots as the problem. Affirming every U.S.-market vaccine, including MMR, is the sentence Cassidy came for. Refusing to say the president erred is the sentence the White House came for. Both can be true in one hearing. They cannot both steer a measles response, a REMS docket, and a foods rehire at the same time without someone losing.

WHAT WE KNOW

• The hearing: Overton testified on September 24 and took written questions through September 25.
• Murray’s vote: Murray said on September 25 that she will vote no, citing the foods-program answers and the mifepristone file.
• The open study: FDA still describes a mifepristone safety study that could change the REMS after analysis, validation, and peer review.

WHAT IS UNCONFIRMED

• A committee date: Cassidy has not said when, or whether, he will schedule a vote.
• Swing Republicans: Cassidy, Sen. Susan Collins of Maine, and Sen. Lisa Murkowski of Alaska have not said how they will vote.
• The REMS outcome: No public finding yet says the January 2023 pharmacy rules will stay, tighten, or go.

Cassidy shepherded Kennedy’s confirmation and is now the physician-chair who has to live with an FDA nominee who stood through an order he called wrong. Collins and Murkowski have backed federal abortion access that a tighter mifepristone REMS would cut. Murray is already a no. The files do not wait on that math. Measles cases were still being added the day of the hearing. The lettuce contamination work is still open. The mifepristone study is still in data collection. Whoever sits in the commissioner’s chair will sign the next memo on all three.

Disclaimer: This article is news reporting and analysis of a Senate confirmation hearing and of CDC and FDA records. It is informational only and is not medical, legal, or voting advice. It does not tell anyone whether to take a vaccine, use mifepristone, change a diet, or vote on a nomination; those choices belong with a licensed physician, a pharmacist, or, for the confirmation, the reader’s own judgment. Figures and agency statuses match the CDC, FDA, hearing, and briefing records named above and can change as the measles count, the lettuce investigation, the mifepristone study, and the nomination move.